S050 Psoriasis
DESCRIPTION
Join us for an exciting session packed with the latest developments in psoriasis therapies for 2027! Curious about emerging oral therapies? Wondering how to manage pediatric psoriasis, generalized pustular psoriasis, psoriatic arthritis, or your most challenging cases? Could earlier intervention improve long-term outcomes? Confused about whether it’s psoriasis or eczema? Want to hear about next-generation topical therapies? You will find all the latest in this lively session. The session also features a spirited showdown between two leading experts debating the ultimate question, “Will we cure psoriasis in our lifetime?” It will be Pso Pstimulating!
LEARNING OBJECTIVES
Evaluate emerging oral therapies, IL-17 and IL-23 inhibitors, and novel topical treatments for psoriasis, and apply the latest clinical evidence to optimize therapeutic selection.
Develop individualized treatment strategies for challenging psoriasis presentations, including pediatric and pustular psoriasis, psoriatic arthritis, and overlapping psoriasis and eczema.
Assess the impact of early therapeutic intervention on long-term psoriasis outcomes and examine emerging evidence for disease modification, sustained remission, and the potential for cure.
SCHEDULE
9:00 AM
Welcome and Introduction
April W. Armstrong, MD, MPH, FAAD
9:05 AM
Pediatric Psoriasis: New Discoveries, New Possibilities
Kelly M. Cordoro, MD, FAAD
9:20 AM
The Oral Revolution: The next frontier in psoriasis management
April W. Armstrong, MD, MPH, FAAD
9:25 AM
When Psoriasis Defies the Playbook: Tackling the Toughest Cases
9:50 AM
Psoriasis or Eczmea? When the Lines Blur
Bruce Elliot Strober, MD, PhD, FAAD
10:05 AM
What is New in Topical Therapies for Psoriasis?
Leon H. Kircik, MD, FAAD
10:20 AM
Pustular Psoriasis: A New Era of Targeted Treatment
Kristina Patrice Callis-Duffin, MD, FAAD
10:35 AM
Making the Case for Early Intervention in the Treatment of Psoriasis
10:50 AM
Therapeutic Advances in Psoriasis and Psoriatic Arthritis
Andrew Blauvelt, MD, FAAD
11:05 AM
The Great Debate: Will We Cure Psoriasis in Our Lifetime?
Kenneth B. Gordon, MD, FAAD
11:45 AM
Question and Answer
DIRECTOR
April W. Armstrong, MD, MPH, FAAD
University of California Los Angeles
DISCLOSURES
April W. Armstrong, MD, MPH, FAAD
AbbVie – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Alumis – Investigator(Grants/Research Funding); Amgen – Advisory Board(Honoraria); Arcutis Biotherapeutics – Consultant(Honoraria); Boehringer Ingelheim – Data Safety Monitoring Board(Honoraria); Bristol-Myers Squibb – Consultant (1099 relationship)(Honoraria); Dermsquared – Advisory Board(Honoraria); Eli Lilly and Company – Advisory Board(Honoraria); Galderma USA – Advisory Board(Honoraria); Incyte – Consultant (1099 relationship)(Honoraria); Janssen Biotech – Consultant (1099 relationship)(Honoraria); Leo Pharma Inc – Consultant(Honoraria); Novartis – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Oruka Therapeutics – Investigator(Grants/Research Funding); Pfizer Inc. – Advisory Board(Honoraria); Regeneron – Advisory Board(Honoraria); Sanofi Genzyme – Consultant(Honoraria); Sun Pharmaceutical Industries Ltd. – Advisory Board(Honoraria); Takeda Pharmaceuticals USA Inc – Advisory Board(Honoraria), Investigator(Grants/Research Funding); UCB – Advisory Board(Honoraria);